ИСПОЛЬЗОВАНИЕ НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ СРЕДСТВ И РИСК КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ
- Авторы: Чичасова Н.В1
-
Учреждения:
- ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москва
- Выпуск: № 9 (2014)
- Страницы: 88-95
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/286981
- ID: 286981
Цитировать
Полный текст



Аннотация
Нестероидные противовоспалительные средства (НПВС) увеличивают риск кардиоваскулярных осложнений и кардиоваскулярной смертности независимо от их селективности в отношении ингибиции циклооксигеназы-2 (ЦОГ-2). В статье обобщены данные рандомизированных контролируемых и наблюдательных исследований по кардиоваскулярной безопасности НПВС. Среди селективных ингибиторов ЦОГ-2 наименьшим риском развития инфаркта миокарда обладает мелоксикам. Среди неселективных НПВС наименьшим кардиоваскулярным риском обладает напроксен. Тем не менее развитие любого кардиоваскулярного осложнения возможно при использовании любого НПВС, особенно лицами с коморбидными сердечно-сосудистыми заболеваниями. В связи с этим рекомендации использования как можно более низких доз НВПС и в более короткие сроки представляются весьма обоснованными.
Полный текст

Об авторах
Н. В Чичасова
ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России, Москвад.м.н., проф. кафедры ревматологии ФППОВ
Список литературы
- Насонов Е.Л. Болевой синдром при патологии опорно-двигательного аппарата. Врач 2002; 4: 15-9.
- Каратеев А.Е., Алексеева Л.И., Филатова Е.Г. и др. Обезболивающая терапия в терапевтической практике. М., 2013. С. 66-85.
- Janssen M., Dijkmans B., van der Sluijs F.A. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br. J. Rheum. 1992; 31: 747-52.
- Solomon S.D., McMuray J.J., Pfeffer M.A., et. al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005; 352: 1071-80.
- Bombardier C., Laine L., Reiein A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000; 343: 1520-28.
- Kadam U.T., Jordan K., Craft P.R. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Walls. Ann Rheum Dis. 2004; 63: 408-14.
- Caporali R., Cimmino M.A., Sazzi-Puttini P., et al. Osteoarthritis in general and specialist practice in Italy: the AMICA study. Sem. Arthr. Rheumat. 2006; 35: 31-7.
- Верткин А.Л., Наумов А.В. Остеоартроз: стратегия ведения больных при соматической патологии. РМЖ. 2007; 15(4): 1-6.
- Верткин А.Л., Алексеева Л.И., Наумов А.В. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16(7): 24-9.
- Rosemann T., Laux G., Szecsenyi J. Osteoarthritis: quality of life, comorbidities, medication and health service utilization assessed in a large sample of primary care patients. J. Orthoped. Surg. 2007; 2: 12
- van Dijk G.M., Venhof C., Schellevis F., et al. Comorbidity, limitation in activities and pain in patients with osteoarthritis of the hip or knee. BMS Musculoskeletal Disord. 2008; 9: 95-9.
- Antman E.M., DeMets D., Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005; 112: 759-70.
- Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
- Topper J.N., Cai J., Falb D., Gimbrone M.A. Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA 1996; 93: 10417-22.
- Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007; 42: 3-27.
- Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase inhibition and beyond. J. Pharm. Parm. Sci. 2008; 11: 81S-110S.
- Timmers L., Sluijter J.P., Verlaan C.W., et al. Cyclooxigenase-2 inhibition increase mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation.2007; 116: 326-32.
- Francois H., Athirakul K., Howell D., et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005; 2: 201-07.
- Hippisley-Cox J., Coupland C. Risk of myocardial infarction in patients taking cyclo-oxigenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ. 2005; 330: 1366.
- Johnsen S.P., Larsson H., Tarone R.E., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, an over NSAIDs: a population-based case-control study. Arch. Int. Med. 2005; 165: 978-84.
- Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007; 370: 2138-51.
- Dai C., Stafford R.S., Alexander G.C. National trends in cyclo-oxigenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch. Intern. Med. 2005; 165: 171-77.
- Garcia Rodriguez L.A., Tacconelli S., Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 2008; 52: 1628-36.
- Levesque L.E., Brophy J.M., Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ. 2006; 174: 1563-69.
- Antman E.M., Bennett J.S., Daugherty A., et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115: 1634-42.
- Minuz P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event? J. Am. Coll. Cardiol. 2008; 52: 1637-39.
- Solomon S.D., Vittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008; 117: 2104-13.
- Cardiovascular and cerebrovascular events in randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin. Trials. 2006; 1: 33.
- Ladacos S.W. Time-to-event analysis for longterm treatments - the APPROVe trial. N. Engl. J. Med. 2006; 355: 113-17.
- Layton D., Heely E., Hughes K., Shakir S. Comparison of the incidence of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheum. 2003; 42: 1342-53.
- Layton D., Hughes K., Harris S., Shakir S. Comparison of the incidence of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatol. 2003; 42: 1 354-64.
- Cannon C.P., Curris S.P., FitzGerald G.A., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet. 2006; 368: 1771-81.
- Singh G. Meloxicam does not increase the risk of acute myocardial infarction, congestive heart failure, edema or hypertension compared to NSAIDs: results from a pooled analysis of 27039 patients [abstract]. Eur. Congress Rheumatology. Prague, 2001, June 13-6.
- Van Ryn J., Kink-Einbad M., Kuritsch I., et al. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. Clin. Pharm. 2004; 44: 777-84.
- Singh G. Comparison of risk of acute myocardial infarction of selective and non-selective antiinflammatory drugs. Ann. Rheum. Dis. 2006; 65(Suppl II): 61.
- Altman A., Luciardi H., Muntaner J., et al. Efficacy assessment of meloxicam, a preferential cyclooxigenese-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the non-steroidal anti-inflammatory drugs in instable angina treatment-2 (NUT-2) pilot study. Circulation. 2002; 106: 191-95.
- Lewis M.F., Miller D.R., Rahme E., et, al. Comparison of the evidence myocardial infarction in patients treated selective and non-selective inhibitors COX-2. Pharmacoepidemiol. Drug Saf. 2006; 15: S59.
- Fosbol E.L., Gislason G.H., Jacobsen S., et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin. Pharmacol. Ther. 2009; 85: 190-97.
- Gislason G.H., Jcobsen S., Rasmussen J.N., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction, Circulation. 2006; 113: 2906-13.
- Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxigenase selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet. 2005; 365: 475-81.
- Brophy J.M., Levesque L.E., Zhang B. The coronary risk of cyclo-oxigenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007; 93: 189-94.
- Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxigenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherotrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332; 1302-08.
- Tai-Juan A., Haas S.J., Liew D., Kran H. Metaanalysis of cyclooxygenase-2 inhibitors and their effect on blood pressure. Arch Int. Med. 2005; 165: 490-96.
- Scott P.A., Kingsley G.H., Scott D. Nonsteroidal anti-inflammatory drugs and cardiac failure meta-analysis of observations studies and randomised trials. Eur. J. Heart Failure. 2007; 10: 1102-07.
Дополнительные файлы
